2 weeks Ago By ABMN Staff
Amgen Inc. ( NASDAQ:AMGN – Free Report ) – Cantor Fitzgerald upped their FY2024 earnings per share (EPS) estimates for shares of Amgen in a research note issued on Thursday, October 31st. Cantor Fitzgerald analyst O.
Brayer now expects that the medical research company will post earnings per share of $19.61 for the year, up from their previous forecast of $19.48.
Cantor Fitzgerald currently has a “Overweight” rating and a $405.00 target price on the stock. The consensus estimate for Amgen’s current full-year earnings is $19.
49 per share. A number of other research analysts have also commented on AMGN. Truist Financial lowered Amgen from a “buy” rating to a “hold” rating and upped their price objective for the company from $320.
00 to $333.00 in a report on Monday, October 14th. Jefferies Financial Group reaffirmed a “buy” rating and set a $380.
00 target price (up from $375.00) on shares of Amgen in a report on Wednesday, August 7th. StockNews.
com raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Dbs Bank upgraded Amgen to a “strong-buy” rating in a research report on Monday, September 16th. Finally, UBS Group cut their price objective on shares of Amgen from $335.
00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock.
According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $333.50.
Amgen Stock Performance Shares of AMGN stock opened at $319.29 on Monday. Amgen has a 52 week low of $260.
52 and a 52 week high of $346.85. The company has a market capitalization of $171.
56 billion, a price-to-earnings ratio of 40.88, a PEG ratio of 2.81 and a beta of 0.
60. The company has a 50-day simple moving average of $324.12 and a 200 day simple moving average of $316.
64. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.
96 and a current ratio of 1.32. Amgen ( NASDAQ:AMGN – Get Free Report ) last released its quarterly earnings data on Wednesday, October 30th.
The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.
47. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.
50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.
00%. The business’s revenue for the quarter was up 23.2% compared to the same quarter last year.
During the same quarter in the prior year, the company earned $4.96 earnings per share. Amgen Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th.
Shareholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. The ex-dividend date of this dividend is Monday, November 18th.
This represents a $9.00 dividend on an annualized basis and a yield of 2.82%.
Amgen’s payout ratio is currently 115.24%. Institutional Investors Weigh In On Amgen Several institutional investors and hedge funds have recently made changes to their positions in the business.
Salomon & Ludwin LLC grew its holdings in Amgen by 11.0% in the first quarter. Salomon & Ludwin LLC now owns 776 shares of the medical research company’s stock worth $221,000 after purchasing an additional 77 shares during the period.
Nikko Asset Management Americas Inc. bought a new position in shares of Amgen in the first quarter valued at $1,993,000. Central Pacific Bank Trust Division acquired a new stake in shares of Amgen in the 1st quarter worth about $414,000.
Proficio Capital Partners LLC boosted its stake in Amgen by 10.5% during the 1st quarter. Proficio Capital Partners LLC now owns 1,611 shares of the medical research company’s stock valued at $458,000 after purchasing an additional 153 shares during the last quarter.
Finally, CapWealth Advisors LLC increased its holdings in Amgen by 0.7% during the 1st quarter. CapWealth Advisors LLC now owns 30,212 shares of the medical research company’s stock worth $8,590,000 after purchasing an additional 224 shares in the last quarter.
Institutional investors own 76.50% of the company’s stock. About Amgen ( Get Free Report ) Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide.
The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. Read More Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter .
.
